FDA WARNING_LETTER - Chris Walsh, c/o Dynadot Privacy

The FDA issued a Warning Letter to trustmeds.com for offering violative products for sale, including "Acomplia (Generic)," "Acomplia (Brand)," "Rimonabant," "Viagra (Brand)," and "Prozac (Generic)." These products are considered drugs under section 201(g) of the Federal Food, Drug, and Cosmetic Act (the Act).

The firm is marketing unapproved new drugs, specifically "Acomplia (Generic)," "Acomplia (Brand)," and "Rimonabant," which are "new drugs" under section 201(p) of the Act. Their introduction into interstate commerce without FDA-approved applications violates sections 301(d) and 505(a) of the Act. Rimonabant (Acomplia) was previously rejected for FDA approval due to safety concerns, including neurological and psychiatric side effects.

Additionally, products like "Viagra (Brand)" and "Prozac (Generic)" are misbranded under section 503(b)(1) of the Act because they are sold without requiring a prescription from a licensed practitioner, violating sections 301(a), 301(b), and 301(k). The website also falsely claims products are FDA-approved, making them misbranded under section 502(a) of the Act due to false and misleading labeling, violating section